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A B S T R A C T
Purpose
In this multicenter study, we evaluated the cumulative burden of morbidity (CBM) among . 1,200
testicular cancer survivors and applied factor analysis to determine the co-occurrence of adverse
health outcomes (AHOs).
Patients and Methods
Participants were # 55 years of age at diagnosis, ﬁnished ﬁrst-line chemotherapy $ 1 year pre-
viously, completed a comprehensive questionnaire, and underwent physical examination. Treat-
ment data were abstracted from medical records. A CBM score encompassed the number and
severity of AHOs, with ordinal logistic regression used to assess associations with exposures.
Nonlinear factor analysis and the nonparametric dimensionality evaluation to enumerate contributing
traits procedure determined which AHOs co-occurred.
Results
Among 1,214 participants, approximately 20% had a high (15%) or very high/severe (4.1%) CBM
score, whereas approximately 80% scored medium (30%) or low/very low (47%). Increased risks of
higher scoreswere associatedwith four cycles of either ifosfamide, etoposide, and cisplatin (odds ratio
[OR], 1.96; 95% CI, 1.04 to 3.71) or bleomycin, etoposide, and cisplatin (OR, 1.44; 95% CI, 1.04 to
1.98), older attained age (OR, 1.18; 95% CI, 1.10 to 1.26), current disability leave (OR, 3.53; 95% CI,
1.57 to 7.95), less than a college education (OR, 1.44; 95% CI, 1.11 to 1.87), and current or former
smoking (OR, 1.28; 95%CI, 1.02 to 1.63). CBMscore did not differ after either chemotherapy regimen
(P = .36). Asian race (OR, 0.41; 95% CI, 0.23 to 0.72) and vigorous exercise (OR, 0.68; 95% CI, 0.52 to
0.89) were protective. Variable clustering analyses identiﬁed six signiﬁcant AHO clusters (x2 P, .001):
hearing loss/damage, tinnitus (OR, 16.3); hyperlipidemia, hypertension, diabetes (OR, 9.8); neurop-
athy, pain, Raynaud phenomenon (OR, 5.5); cardiovascular and related conditions (OR, 5.0); thyroid
disease, erectile dysfunction (OR, 4.2); and depression/anxiety, hypogonadism (OR, 2.8).
Conclusion
Factors associated with higher CBM may identify testicular cancer survivors in need of closer
monitoring. If conﬁrmed, identiﬁed AHO clusters could guide the development of survivorship care
strategies.
J Clin Oncol 36:1505-1512. © 2018 by American Society of Clinical Oncology
INTRODUCTION
The number of cancer survivors has increased
markedly in recent decades, with an estimated 18
million in the United States by 2022.1 Given these
increasing numbers, having an understanding
and quantifying the late effects of cancer and its
treatment to inform survivorship care strategies
are important. An important population in which
to assess adverse health outcomes (AHOs) are
survivors of testicular cancer, the most common
cancer in men ages 18 to 39 years.2 Since effective
cisplatin-based chemotherapy was introduced in
the 1970s,3 the overall age-adjusted 5-year relative
survival rate is . 95%,4 and survivors remain at
risk for decades for the late effects of cancer
and its treatment. Characterization of AHOs is
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facilitated by the homogeneity of treatment regimens. For four
decades, therapy for advanced testicular cancer typically has
consisted of platinum-based chemotherapy. For good-risk disease,
standard treatment comprises either three cycles of bleomycin,
etoposide, and cisplatin (BEP3 3) or four cycles of etoposide plus
cisplatin (EP 3 4), whereas for intermediate- or poor-risk tes-
ticular cancer, four cycles of BEP (BEP 3 4) or four cycles of
etoposide, ifosfamide, and cisplatin (VIP3 4) are administered.5,6
Although treatment of good-risk testicular cancer with BEP 3 3
versus EP3 4 results in lower cisplatin exposure, it is accompanied
by potential bleomycin adverse effects.7 To our knowledge, no
study has evaluated the cumulative burden of morbidity (CBM)
after BEP3 4 versus VIP3 4 or after BEP3 3 versus EP3 4 and
has taken into account both the number and the severity of AHOs.
Such characterization is important to develop risk-stratiﬁed,
evidence-based follow-up recommendations. Moreover, as noted
previously,8 a better understanding of AHOs may help to guide
testicular cancer management, especially in the controversial area
of whether good-risk patients should receive EP 3 4 or BEP 3 3.
To provide new information about CBM after contemporary
cisplatin-based chemotherapy for testicular cancer, we examined
both the number and the severity of AHOs among 1,214 testicular
cancer survivors enrolled in the Platinum Study, a large, multi-
center clinical investigation.9 We evaluated the co-aggregation of
AHOs to identify co-occurring clusters and identiﬁed clinical,
sociodemographic, and behavioral factors associated with an el-
evated CBM.
PATIENTS AND METHODS
Study Population
The Platinum Study was approved by each participating institution’s
institutional review board, and all participants provided written informed
consent. The cohort was described in detail previously.2,10 Brieﬂy, eligible
testicular cancer survivors had a histologic/serologic diagnosis of germ cell
tumor, were age # 55 years at diagnosis, completed ﬁrst-line cisplatin-
based chemotherapy $ 1 year previously, and were undergoing routine
follow-up at the participating site. All participants are referred to as
testicular cancer survivors. At study enrollment, participants reported
current prescription medication use with indication, underwent a brief
physical examination, and completed comprehensive health question-
naires. Cancer diagnosis and treatment data were abstracted from medical
records (Appendix, online only). Testicular cancer survivors indicated the
average time per week of participating in various physical activities during
the past year.11,12 These activities were grouped into vigorous ($ 6
metabolic equivalent tasks) and nonvigorous (, 6 metabolic equivalent
tasks) activities (Appendix).13
Measurement of AHOs
Participant responses were mapped to individual AHOs and graded
according to severity on a 0 to 4-point scale using a modiﬁed version of the
National Cancer Institute Common Terminology Criteria for Adverse
Events (version 4.03)14 as in prior studies.15,16 A multidisciplinary panel of
experts agreed on all grades (C.F., H.D.S., D.M.S., S.D.F., L.H.E., and
L.B.T.). Appendix Table A1 (online only) lists individual AHOs and
grading criteria.15,16 If no response was provided (, 1%), the AHO was
conservatively treated as no symptom/diagnosis. CBM score was calculated
on the basis of the number and severity of AHOs by following methods
adapted from Geenen et al15 (Appendix Table A2, online only). A sec-
ondary CBM score, CBMPt, was calculated using AHOs previously related
to cisplatin exposure (ie, peripheral sensory neuropathy, autonomic
neuropathy, hearing damage, tinnitus, kidney disease).17,18
Statistical Analysis
Discrete and continuous data were described using numbers (per-
centages) and medians (ranges), respectively. Sociodemographic, health
behavior, and treatment variables were individually tested for association
with CBM score using t (continuous variables) or Pearson’s x2 (categorical
variables) test. Variables then were combined in a multivariable ordinal
logistic regression model, with CBM score as the dependent variable.
Unless otherwise noted, variables with Wald x2 P value $ .1 in the full
model were removed from the ﬁnal model. In the latter, the very high and
severe CBM categories were collapsed given sparse data. Multivariable
models that investigated the effect of cumulative cisplatin dose on CBMPt
score included the same covariates as the main model, except that che-
motherapy regimen was omitted given its strong correlation with cu-
mulative cisplatin dose.
Ordinal logistic regression examined the relationship between CBM
score and self-reported health (the dependent variable). For all ordinal
logistic regression models, the assumption of proportionality of odds
across response categories was conﬁrmed by comparing the Bayesian in-
formation criterion for the proportional odds model to that from a partial
proportional odds model. Stata 14.1 software (StataCorp; College Station,
TX) was used for all descriptive statistics and regression analyses.
Cluster analysis of variables was performed with nonlinear factor
analysis and the nonparametric conditional item-pair covariance method
of the cross-validated dimensionality evaluation to enumerate contributing
traits procedure (Appendix). Each AHO was dichotomized: grades 0 and 1
were combined, and grades 2, 3, and 4 were combined. Because of sparse
numbers, transient ischemic attack and stroke were collapsed into a single
AHO; hypertriglyceridemia and hypercholesterolemia were combined into
hyperlipidemia. Average item-pair odds ratios (ORs) were calculated by
averaging the log OR across AHO pairs and then by exponentiating the
average value.
RESULTS
Median age at evaluation for 1,214 testicular cancer survivors was 37
years (range, 18 to 74 years), and median time since chemotherapy
completion was 4.2 years (range, 1 to 30 years; Table 1). Of all
participants, 1,157 (95.3%) were seen in the clinic during routine
follow-up care, and approximately 90% completed chemotherapy
within 15 years of enrollment. Most participants (1,035 [85.3%])
received BEP3 3 (460 [37.9%]), BEP3 4 (222 [18.3%]), or EP3 4
(353 [29.1%]); 44 receivedVIP, typically four cycles (n = 32).Median
cumulative cisplatin dose was 400 mg/m2, with approximately one
third receiving 300 mg/m2 (447 [36.8%]). Retroperitoneal lymph
node dissection was performed in 46.3% of participants. Most
survivors were white (85.3%), married/living as married (61.0%),
employed (88.7%), and educated beyond high school (88.3%).
The most prevalent AHOs of any severity were obesity (41.7%
grade 2, 26.0% grade 3, 3.9% grade 4), sensory neuropathy (28.3%
grade 1, 14.5% grade 2, 13.4% grade 3), tinnitus (25.0% grade 1,
7.1% grade 2, 7.5% grade 3), and hearing damage (24.5% grade 1,
13.5% grade 2, 1.2% grade 3; Table 2). Raynaud phenomenon
occurred in approximately 33% of participants (15.6% grade 1,
8.7% grade 2, 9.1% grade 3) and pain in approximately 25%
(13.6% grade 1, 9.8% grade 2, 1.5% grade 3). Hypogonadism
(10.2% grade 2) and erectile dysfunction (15.9% grade 1, 12.5%
grade 2) also were observed.
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Table 1. Clinical, Sociodemographic, and Health Behavior Characteristics of
1,214 Survivors of Cisplatin-Treated Germ Cell Tumors
Clinical Characteristic No. (%)
Age at diagnosis, yearsa
Median (range) 30 (15-60)
, 20 89 (7.3)
20-29 482 (39.7)
30-39 403 (33.2)
$ 40 232 (19.2)
Age at evaluation, years
Median (range) 37 (18-74)
, 20 9 (0.7)
20-29 265 (21.8)
30-39 436 (35.9)
40-49 314 (25.9)
50-59 164 (13.5)
60-69 26 (2.1)
Calendar year of diagnosisb
Before 2000 146 (12.0)
2000-2004 145 (11.9)
2005-2009 317 (26.1)
2010-2016 598 (49.3)
Histologic type
Seminoma 310 (25.5)
Nonseminoma 885 (72.9)
Not otherwise speciﬁed 19 (1.6)
Tumor sitec
Testis 1,069 (88.1)
Extragonadal 135 (11.1)
Type of cisplatin-based chemotherapyd
BEP, cycles 710 (58.5)
# 2 21
3 460
4 222
$ 5 7
EP, cycles 388 (32.0)
# 3 23
4 353
$ 5 12
VIP, cycles 44 (3.6)
3 4
4 32
$ 5 8
Othere, cycles 69 (5.7)
# 2 11
3 8
4 41
$ 5 9
Cumulative dose of cisplatin, mg/m2f
Median (range) 400 (100-828)
, 300 61 (4.9)
300 447 (36.8)
301-399 44 (3.2)
400 589 (48.5)
. 400 55 (4.4)
Retroperitoneal lymph node dissectiong
Yes 562 (46.3)
No 639 (52.6)
Time since completion of chemotherapy, yearsh
Median (range) 4.2 (1-30)
, 2 329 (27.1)
2-5 423 (34.8)
6-9 186 (15.3)
$ 10 261 (21.5)
Sociodemographic characteristic
Racei
White 1,036 (85.3)
African American 16 (1.3)
(continued in next column)
Table 1. Clinical, Sociodemographic, and Health Behavior Characteristics of
1,214 Survivors of Cisplatin-Treated Germ Cell Tumors (continued)
Clinical Characteristic No. (%)
Asian 59 (4.9)
Other 68 (5.6)
Marital statusj
Single or never married 389 (32.0)
Married/living as married 740 (61.0)
Widowed, divorced, separated 70 (5.8)
Educationk
High school or less 139 (11.5)
After high school but not college graduate 289 (23.8)
College or university graduate 508 (41.9)
Postgraduate 275 (22.7)
Employment statusl
Unemployed 74 (6.1)
Employed 1,077 (88.7)
Retired 15 (1.2)
On disability leave 30 (2.5)
Health behavior
Smoking statusm
Never 714 (58.8)
Former 392 (32.3)
Current 107 (8.8)
Average No. of alcoholic drinks in past yearn
Rarely or never 239 (19.7)
1-3/mo 180 (14.8)
1-6/wk 569 (46.9)
$ 1/d 218 (18.0)
Engage in vigorous physical activity ($ 6 METs)o
Yes 835 (68.8)
No 378 (31.1)
Abbreviations: BEP, bleomycin, etoposide, and cisplatin; EP, etoposide and
cisplatin; MET, metabolic equivalent task; VIP, etoposide, ifosfamide, and
cisplatin.
aAge at diagnosis was not available for eight participants.
bYear of diagnosis was not available for eight participants.
cTumor site was not available for 10 participants.
dOf the 52 participants treated with VIP 3 4, 44% had mediastinal disease,
whereas 47% had disease conﬁned to the testis; in the remainder (9%), other
extragonadal sites were involved. This contrasts with the smaller percentage of
participants with mediastinal disease (ie,# 7.2%) in the other treatment groups.
eOther chemotherapy regimens were cisplatin and ifosfamide (n = 25); cis-
platin, vinblastine, and bleomycin (n = 6); ifosfamide, bleomycin, cisplatin, and
etoposide (n = 6); and other cisplatin-based regimens (n = 32). The number of
cycles was not available for four participants who received a chemotherapy
regimen designated as other.
fCumulative dose of cisplatin was not available for 18 participants.
gRetroperitoneal lymph node dissection statuswas not available for 13 participants.
hTime since completion of chemotherapy was not available for 15 participants.
iRace was not stated for 19 participants.
jMarital status was not stated for 15 participants.
kEducation status was not stated for three participants.
lEmployment status was not stated for 18 participants.
mSmoking status was not stated for one participant.
nAlcohol consumption was not stated for eight participants.
oExercise was assessed in this study with a validated questionnaire11,12 that
asks participants to report their average time per week (over the past year) spent
at each of nine recreational activities: walking or hiking (including walking to
work); jogging (. 10 min/mile); running (# 10 min/mile); bicycling (including
stationary bike); aerobic exercise/dance or exercise machines; lower-intensity
exercise, yoga, stretching, or toning; tennis, squash, or racquetball; lap swim-
ming; and weight lifting or strength training. Each physical activity was assigned
aMET value, which is a commonly usedmetric for describing the relative energy
expenditure of a speciﬁc type of physical activity (1 MET = 1 kcal/kg/h or the
energy cost of sitting quietly). TheMET values for each activity were then used to
calculateMET-h/wk for each participant, and these were grouped into categories
of vigorous or nonvigorous physical activity according to standard deﬁnitions.13
Physical activity was not stated for one participant.
jco.org © 2018 by American Society of Clinical Oncology 1507
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Figure 1 shows the CBM scores. Approximately 20% of
participants had a high (180 [14.8%]), very high (46 [3.8%]), or
severe (one [0.1%]) score, whereas 76% had a very low (104
[8.6%]), low (458 [37.7%]), or medium (360 [29.7%]) score. Only
5.4% of participants had no AHOs. All 47 with a very high or severe
CBM score had grade 4 obesity.
Bivariable associations of clinical, sociodemographic, and health
behavior factors with CBM score are shown in Appendix Table A3
(online only). In a multivariable model (Table 3) that controlled for
time since chemotherapy and enrollment center, the following were
signiﬁcantly associated with higher CBM score: older attained age
(OR, 1.18 per 5 years), BEP3 4 (OR, 1.44 v BEP3 3), VIP3 4 (OR,
1.96 v BEP 3 3), less than a college-level education (OR, 1.44),
current disability leave (OR, 3.53), and former or current smoking
status (OR, 1.28). Although the OR for VIP 3 4 was slightly higher
than that for BEP 3 4, the difference was not signiﬁcant (P = .36).
Disease stage was not associated with CBM score (P = .48), which
suggests that increased scores after BEP 3 4 or VIP 3 4 were not
explained by more-advanced tumor status. CBM scores after EP3 4
and BEP 3 3 were similar (P = .65). No signiﬁcant differences were
observed for individual AHOs except Raynaud phenomenon (P ,
.001), for which prevalence and severity after BEP3 3 (183 [39.8%]:
18.5% grade 1, 10.4% grade 2, 10.9% grade 3) exceeded EP3 4 (84
[23.8%]: 12.2% grade 1, 16.8% grade 2, 4.8% grade 3).
Asian race (OR, 0.41) and vigorous exercise (OR, 0.68) were
inversely associated with higher CBM score. Lower risk in Asian
testicular cancer survivors reﬂects that fewer participants had
higher severity grades for 15 of 22 AHOs versus white survivors
(eg, peripheral sensory neuropathy: 8.5% v 13.5% grade 3; hearing
loss: 8.5% v 14.1% grade 2, 0% v 1.2% grade 3). Similar trends were
observed for autonomic neuropathy, tinnitus, Raynaud phe-
nomenon, pain, kidney disease, hypertension, coronary artery
disease, peripheral artery disease, obesity, thyroid disease,
depression/anxiety, erectile dysfunction, and hypogonadism.
The relationship between cumulative cisplatin dose and overall
CBM score was of borderline signiﬁcance (OR per 100 mg/m2,
Table 2. Prevalence of Adverse Health Outcomes By Severity Grade
Adverse Health Outcome
Severity Grade, No. (%)
All 1 2 3 4
Peripheral sensory neuropathy* 683 (56.3) 344 (28.3) 176 (14.5) 163 (13.4) NA†
Autonomic neuropathy‡§ 323 (26.6) 234 (19.3) 68 (5.6) 21 (1.7) NA
Hearing damage‡ 476 (39.2) 297 (24.5) 164 (13.5) 15 (1.2) 0
Tinnitus‡ 481 (39.6) 304 (25.0) 86 (7.1) 91 (7.5) NA
Raynaud phenomenon‡ 405 (33.4) 189 (15.6) 105 (8.7) 111 (9.1) NA
Pain* 302 (24.9) 165 (13.6) 119 (9.8) 18 (1.5) NA
Kidney disease* 30 (2.5) 27 (2.2) 3 (0.3) NA NA
Hypercholesterolemia* 96 (7.9) NA 96 (7.9) NA NA
Hypertriglyceridemia* 6 (0.5) NA 6 (0.5) NA NA
Hypertension* 114 (9.4) NA 114 (9.4) NA NA
Diabetes* 37 (3.0) NA 20 (1.7) 17 (1.4) NA
Coronary artery disease* 20 (1.6) 4 (0.3) 7 (0.6) 9 (0.7) NA
Transient ischemic attack‡ 8 (0.7) 8 (0.7) NA NA NA
Stroke‡ 6 (0.5) NA 6 (0.5) NA 0
Peripheral artery disease* 56 (4.6) 27 (2.2) 14 (1.2) 15 (1.2) NA
Thromboembolic event* 88 (7.2) NA 44 (3.6) 44 (3.6) NA
Obesityk 868 (71.5) NA¶ 506 (41.7) 315 (26.0) 47 (3.9)
Thyroid disease* 39 (3.2) 20 (1.7) 19 (1.6) NA NA
Anxiety and/or depression# 75 (6.2) NA 75 (6.2) NA NA
Erectile dysfunction* 345 (28.4) 193 (15.9) 152 (12.5) NA NA
Hypogonadism# 124 (10.2) NA 124 (10.2) NA NA
Abbreviation: NA, not applicable.
*On the basis of patient-reported outcomes and prescription medication use.
†NA because data needed to assign these toxicities according to the Common Terminology Criteria for Adverse Events (version 4.03) deﬁnitions were not captured in
the current study.
‡On the basis of patient-reported outcomes.
§Among participants with grade 0, 1, 2, and 3 autonomic neuropathy, 22, seven, two, and one, respectively, reported that they take a b-blocker.
kCalculated using weight and height assessments from the physical examination conducted at clinical evaluation.
¶Common Terminology Criteria for Adverse Events (version 4.03) does not include a grade 1 for obesity.
#On the basis of prescription medication use.
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Fig 1. Distribution of cumulative burden of morbidity (CBM) score among 1,214
participants in the Platinum Study.
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1.16; 95% CI, 0.99 to 1.37; P = .064) in the multivariable model.
However, when limited to conditions previously attributed to
cisplatin,14,15 each 100 mg/m2 increase in cumulative dose was
associated with signiﬁcantly worse CBMPt (OR per 100mg/m
2, 1.34;
95% CI, 1.14 to 1.58; P , .001).
Increasing CBM score was signiﬁcantly associated with worse
self-reported health. Compared with testicular cancer survivors
with a score of 0, the risk of worse self-reported health among those
scored as very low, low, medium, high, or very high/severe was 1.94
(95% CI, 1.08 to 3.48), 2.82 (95% CI, 1.72 to 4.62), 5.91 (95% CI,
3.56 to 9.81), 10.90 (95% CI, 6.28 to 18.93), and 34.17 (95% CI,
16.54 to 70.62), respectively.
Results from both variable clustering methods converged in
the analysis of AHOs to yield six major groups of signs/symptoms
(x2 for model ﬁt, P, .001), with pairwise ORs for given clusters as
follows: hearing loss/damage, tinnitus (OR, 16.3); metabolic dis-
orders (diabetes, hypertension, hyperlipidemia; OR, 9.8); neu-
ropathy and related conditions (sensory neuropathy, autonomic
neuropathy, pain, Raynaud phenomenon; OR, 5.5); cardiovascular
disease (CVD) and related conditions (coronary artery disease,
stroke, kidney disease, peripheral artery disease, thromboembo-
lism, obesity; OR, 5.0); erectile dysfunction, thyroid disease (OR,
4.2); and hypogonadism, depression/anxiety (OR, 2.8). Clusters
hearing loss/damage, tinnitus and neuropathy and related con-
ditions, although distinct, were strongly correlated (r = 0.658; P,
.001), as were clusters erectile dysfunction, thyroid disease and
hypogonadism, depression/anxiety (r = 0.914; P , .001).
DISCUSSION
To our knowledge, the results are based on the largest study to date
in testicular cancer survivors administered contemporary
cisplatin-based chemotherapy. We characterize the CBM by
showing that even at a young age, approximately one in ﬁve pa-
tients has a score of high to severe, with only 5% reporting no
AHOs. Although CBM was higher in participants treated with
BEP3 4 or VIP3 4 (v BEP3 3), scores did not differ signiﬁcantly
between the two regimens (P = .36). CBM score also did not differ
between BEP 3 3 and EP 3 4, the standard approaches for good-
risk disease. The higher prevalence and severity of Raynaud
phenomenon after BEP 3 3 is consistent with the known re-
lationship with bleomycin,7 although Raynaud phenomenon also
may be related to cisplatin.19 Increasing cumulative cisplatin dose
signiﬁcantly increased risk for a higher CBM score for AHOs
related to neuropathy, ototoxicity, and kidney disease. The strong
association between higher CBM score and worse self-reported
health indicates that the score reﬂects a health status perceptible to
patients. These and other new ﬁndings are discussed next.
Previous US investigations of testicular cancer survivors2,20-24
have been limited in scope, generally by either not addressing
AHOs21,23,24 or evaluating fewer than ﬁve conditions22 (Appendix
Table A4, online only). Although three studies obtained treatment
information from medical records, only Oh et al22 (143 patients)
examined AHOs (n = 4) by therapy. Hashibe et al20 evaluated
AHOs through linkage with International Classiﬁcation of Dis-
eases, Ninth Revision, codes, but results were not presented by
treatment, and only 168 patients received chemotherapy (type
unspeciﬁed). In contrast, we evaluated a wide spectrum of AHOs
by type and severity among . 1,200 testicular cancer survivors
with detailed treatment information. The resultant CBM score
comprises a range of AHOs likely related to testicular cancer and its
treatment and to long-term platinum retention. After chemo-
therapy completion, circulating serum platinum remains mea-
surable at levels up to 1,000 times above normal for 20 years.25
Ongoing endothelial cell and vascular damage26 occur for many years,
and long-term serumplatinum levels have been signiﬁcantly related to
neuropathy,27 hypertension,28 and hypercholesterolemia.28
Table 3. Multivariable Ordinal Logistic Regression of Factors Associated With
Cumulative Burden of Morbidity Score
Variable OR (95% CI) P
Age at evaluation (per 5 years)* 1.18 (1.10 to 1.26) , .001
Time since chemotherapy completion, years
, 2 Ref. —
2-5 0.91 (0.68 to 1.23) .540
6-9 0.61 (0.42 to 0.89) .010
$ 10 0.55 (0.38 to 0.85) .002
Race
White Ref. —
Black/African-American 1.56 (0.49 to 5.03) .450
Asian 0.41 (0.23 to 0.72) .002
Other 1.05 (0.63 to 1.76) .840
Education
College or postcollege graduate Ref. —
Less than college education 1.44 (1.11 to 1.87) .006
Current employment status
Employed Ref. —
Unemployed 0.90 (0.55 to 1.47) .660
Retired 1.10 (0.36 to 3.39) .870
Disability leave 3.53 (1.57 to 7.95) .002
Smoking status
Never Ref. —
Current or former 1.28 (1.02 to 1.63) .037
Vigorous physical activity ($ 6 METs)†
No Ref. —
Yes 0.68 (0.52 to 0.89) .004
Retroperitoneal lymph node dissection‡
No Ref. —
Yes 0.88 (0.69 to 1.12) .310
Type of chemotherapy§, 3 No. of cycles
BEP 3 3 Ref. —
EP 3 4 1.09 (0.75 to 1.60) .650
BEP 3 4 1.44 (1.04 to 1.98) .028
VIP 3 4 1.96 (1.04 to 3.71) .039
NOTE. ORs and P values are from an adjusted model that includes all other
variables listed in the table as well as enrollment center, with cumulative burden
of morbidity score as the outcome (dependent) variable. The very high and
severe categories were collapsed because of sparse data. Analysis includes
1,013 (83.4%) testicular cancer survivors with nonmissing data for all variables in
the model. Boldface indicates signiﬁcance at P , .05.
Abbreviations: BEP, bleomycin, etoposide, and cisplatin; EP, etoposide plus
cisplatin; MET, metabolic equivalent task; OR, odds ratio; Ref., reference; VIP,
etoposide, ifosfamide, and cisplatin.
*Age at diagnosis was not included in the model given the strong correlation
with age at evaluation (r = 0.81), which was included.
†See Table 1 footnote o and the Appendix for details on the assessment of
physical activity.
‡Retroperitoneal lymph node dissectionwas retained in themultivariablemodel
to control for potential residual confounding given its correlation with chemo-
therapy regimen (P , .001); approximately 34%, 55%, 66%, and 44% of tes-
ticular cancer survivors treated with BEP 3 3, EP 3 4, BEP 3 4, and VIP 3 4,
respectively, had a retroperitoneal lymph node dissection.
§Disease stage was not signiﬁcantly associated with cumulative burden of
morbidity score (P = .48), which suggests that increased scores after BEP3 4 or
VIP 3 4 were not explained by a more-advanced tumor status.
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Because testicular cancer occurs largely inwhitemales,29 data on
Asian patients are sparse. Decreased risks of a higher CBM score in
Asian versus white testicular cancer survivors largely reﬂect the lower
occurrence of high-severity grades in Asians for most AHOs. These
include known treatment-related toxicities, which possibly reﬂects
differences in drug absorption, distribution, metabolism, and ex-
cretion, among others. Although we adjusted for sociodemographic
and health behavior factors, other unmeasured inﬂuences may have
accounted for this ﬁnding, which remain to be conﬁrmed.
Although the CBM score was slightly higher after VIP3 4 than
after BEP3 4, the difference was not signiﬁcant (P = .36). Both are
standard chemotherapy regimens for intermediate- and poor-risk
disease5,6 and show equivalent survival. Although an early, ran-
domized trial showed that VIP 3 4 is associated with greater acute
toxicity than BEP3 4,30 no study has subsequently addressed long-
term AHOs as we have done. Additional follow-up, as planned for
this cohort, is required to quantify further the CBM associated with
each regimen. CBM also was similar for BEP3 3 versus EP3 4, the
two commonly applied regimens for good-risk disease. In a curable
disease such as testicular cancer with a long life expectancy and
equivalent therapy options, the availability of AHO data becomes
increasingly important to inform treatment decisions.8
The striking association between CBM score and self-reported
health indicates that the score captures outcomes that affect pa-
tients’ self-perception of health. The risk of worse self-reported
health among patients with very high/severe CBM scores rose to
. 30-fold compared with those with a score of 0. These results also
underscore the need to assess outcomes that affect self-perceived
health because these can guide the development of survivorship
care strategies that patients value.
To our knowledge, we have performed the ﬁrst variable-based
factor analysis of AHOs in long-term cancer survivors. Prior analyses
have largely been conducted in patients either during cancer
treatment,31,32 shortly after therapy completion,33,34 or during
palliative/hospice care.35 Only Kim et al36 evaluated patients who
were either 2 to 5 years (n = 66) or . 5 years (n = 56) postcancer
diagnosis, although some were still undergoing treatment. Factor
analysis provides insights into groups of conditions thatmay co-occur
and perhaps share etiology. For example, hearing loss and tinnitus
reﬂect known cisplatin-associated damage to the auditory system.10,37
Associations between neuropathy and Raynaud phenomenon have
been reported in individuals with no chemotherapy exposure,38,39
although the biologic basis is incompletely understood, and co-
occurrence could reﬂect symptom cross-reporting. Pain is frequently
associated with chemotherapy-induced peripheral neuropathy, with
no agents currently available for prevention or treatment.40
The cluster of hyperlipidemia, hypertension, and diabetes
present at the time of clinical evaluation represents components of
the metabolic syndrome,41 consistent with studies that report
increased metabolic syndrome risk among European testicular
cancer survivors.42-45 The co-occurrence of AHOs related to CVD
supports European investigations who showed a 1.4-fold to seven-
fold higher CVD risk among cisplatin-treated testicular cancer
survivors versus either the general population or patients managed
with surgery alone.26,46-49 Presentation with one or more of these
AHOs suggests closer screening for other cluster-related conditions
that could signal an elevated risk for CVD morbidity and mor-
tality.7 Hypogonadism and depression, respectively, represent
a biologic consequence of testicular cancer treatment50,51 and
possibly associated psychological outcomes. A potential relation-
ship between hypogonadism and depression in the general pop-
ulation has been recognized, with other symptoms including
muscle weakness and loss of energy.52-56
An association of erectile dysfunction and thyroid disease has
not been previously shown in testicular cancer survivors as it has in
noncancer populations.57-63 Of 39 testicular cancer survivors with
thyroid disease, 33 and six reported hypothyroidism and hyperthy-
roidism, respectively. Although associations of hypothyroidism57,62,63
and hyperthyroidism57,61-63 with erectile dysfunction were observed
in several studies in noncancer populations, a relationship with
hypothyroidism was not conﬁrmed in the largest investigation to
date,61 possibly because of the low prevalence, and requires ad-
ditional investigation.
The strong association between vigorous physical activity and
lower CBM score as well as with a reduced absolute number of
AHOs in prior analyses2 can inform future intervention strategies.
Studies of childhood cancer survivors have shown that exercise
reduces the risk of late effects, such as CVD,64 and the same likely
applies to testicular cancer survivors. The apparent inverse relation
between increased risk of a high CBM score and follow-up time is
due to the disproportionate contribution of early-onset toxicities
(eg, neuropathy, tinnitus), which aremore prevalent than later-onset
toxicities (eg, hypercholesterolemia, hypertension), which reﬂects
the relatively short median follow-up time and young cohort age.
A major strength of this study is the estimation of both the
number and the severity of AHOs in a large testicular cancer sur-
vivorship cohort treated primarily with EP3 4, BEP3 3, BEP3 4,
or VIP 3 4 chemotherapy regimens. Other strengths include the
high participation rate (93%), detailed medical chart abstraction,
and estimation of risk without the confounding effect of radio-
therapy. An inherent limitation to all cross-sectional studies is the
inability to assess causality between clinical, sociodemographic, and
health behavior characteristics and CBM score. AHOs largely were
self-reported without baseline data, similar to previous testicular
cancer survivorship studies.21,23,65 As in Geenen et al,15 a limitation
is that we could not compare the CBM score with that of a normative
population given the unavailability of data. Equivalent weight was
assigned to all AHOs, whereas testicular cancer survivorship may
weigh these differently; some AHOs capture symptoms that can
markedly affect survivors (eg, neuropathy), whereas others encompass
conditions treated by medications that may be less bothersome (eg,
hypertension). Additional studies are needed to investigate the effect
of speciﬁc AHOs on health-related quality of life in this under-
studied population.
In conclusion, at a median follow-up of only 4.2 years, ap-
proximately one in ﬁve testicular cancer survivors have a CBM
score of high, very high, or severe. Of note, no difference in CBM
score was observed among survivors who received BEP3 4 versus
VIP3 4 chemotherapy or among those given EP3 4 versus BEP3
3, although the long-termmonitoring of patients is important. The
value of variable clustering analysis in revealing the co-occurrence
of AHOs is underscored by our ﬁndings and should be considered
for other groups of long-term cancer survivors to highlight po-
tential areas of research into the mechanistic bases of toxicities.
Ongoing genetic research in the current cohort has already begun
to characterize biologic pathways that underlie cisplatin-related
1510 © 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
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toxicities66,67 and that can identify new research opportunities
aimed at developing agents to prevent, mitigate, and treat adverse
sequelae not only among testicular cancer survivors but also
among other survivors after cisplatin-based chemotherapy. In the
interim, if conﬁrmed, the current results could inform survivor-
ship care strategies and assist health care providers in identifying
conditions, or groups of conditions, for which to screen, counsel,
and treat testicular cancer survivors.
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Appendix
Methods
Study Population
All participants received ﬁrst-line cisplatin-based chemotherapy for either initial germ cell tumor or recurrence after active
surveillance. Participants could not have received subsequent salvage chemotherapy, radiotherapy, or antecedent chemotherapy for
another primary cancer. All participants were disease free at the time of clinical assessment.
Data Collection From Medical Records and Clinical Evaluation
Study personnel were trained in person to abstract data using a standard protocol and forms modiﬁed from previous in-
vestigations11 (Travis LB, et al: J Natl Cancer Inst 86:1450-1457, 1994; Travis LB, et al: J Natl Cancer Inst 87:524-530, 1995; Travis
LB, et al: N Engl J Med 340:351-357, 1999; Travis LB, et al: J Natl Cancer Inst 94:182-192, 2002). Detailed data on cancer diagnosis
and treatment, including names and doses of all cytotoxic drugs were abstracted directly from medical records.
Sociodemographic Characteristics, Patient-Reported Health Outcomes, and Lifestyle Behaviors
Patient-reported outcomes and lifestyle behaviors were assessed through self-reporting using validated
questionnaires.11,12,68-71 To minimize recall bias, we applied strict deﬁnitions to assessment times. Validated questionnaires that
queried symptoms over the past 4 weeks were selected, and for those adverse health outcomes (AHOs) for which Common
Terminology Criteria for Adverse Events (version 4.03) grading took into account prescription medication use (ie, peripheral
sensory neuropathy, pain, kidney disease, hypercholesterolemia, hypertriglyceridemia, hypertension, diabetes, peripheral artery
disease, thromboembolic event, thyroid disease, anxiety/depression, erectile dysfunction, hypogonadism), we only took into
account current prescription medication use (with usage for . 1 month), with data provided by the patient at the time of clinical
assessment. For sociodemographic characteristics, we assessed current marital and employment status. Self-reported race and
education level were determined at the time of enrollment. For health behaviors, we used standardized questions drawn from
validated survey tools to assess current or former smoking status, alcohol consumption, and physical activity over the past year.
For health behaviors, we used validated questionnaires to assess current or former smoking status, alcohol consumption, and
physical activity over the past year. Exercise was assessed with a validated questionnaire11,12 that asked participants to report their
average time per week (over the past year) spent in each of nine recreational activities: walking or hiking (including walking to
work); jogging (. 10 min/mile); running (# 10 min/mile); bicycling (including stationary bike); aerobic exercise/dance or exercise
machines; lower-intensity exercise, yoga, stretching, or toning; tennis, squash, or racquetball; lap swimming; and weight lifting or
strength training. Each physical activity was assigned ametabolic equivalent task (MET) value, which is a commonly usedmetric for
describing the relative energy expenditure of a speciﬁc type of physical activity (1 MET = 1 kcal/kg/h or the energy cost of sitting
quietly).11 The MET values for each activity were then used to calculate MET-hours per week for each participant, and these were
grouped into categories of vigorous or nonvigorous physical activity according to standard deﬁnitions (Ainsworth, et al: Med Sci
Sports Exerc 43:1575-1581, 2011).
Measurement of AHOs
Symptoms related to a single underlying condition were grouped to avoid overcounting (eg, coronary artery disease was
deﬁned as a single AHO by combining coronary artery disease, angina, heart attack or myocardial infarction, and related pro-
cedures). For 12 AHOs in which current prescription medication use determined grade, medications were only considered if
participants started use during or after cancer treatment.
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Statistical Analysis
Nonlinear factor analysis used the probit link andWLSMV (weighted least squares means and variance) estimation withMplus
software (Muthe´n, et al: 2017) and the nonparametric conditional item-pair covariance method of the cross-validated di-
mensionality evaluation to enumerate contributing traits procedure (Monahan, et al: Appl Psychol Meas 31:483-503, 2007; Zhang,
et al: Psychometrika 64:213-249, 1999) using the expl.detect function from the sirt (supplementary item response theory) R
package (https://CRAN.R-project.org/package=sirt) and its default N.est option of a 50-50 split in training and validation data sets
for replications.
Table A1. AHOs That Comprise the Cumulative Burden of Morbidity Score
AHO and Platinum Study Items Used to Assign
Severity Grade
Grade
1 2 3 4
Peripheral sensory neuropathy A little Quite a bit Very much NA
Tingling ﬁngers/hands or toes/feet*
Numbness in ﬁngers/hands or toes/feet*
Shooting or burning pain in ﬁngers/hands
or toes/feet*
Difﬁculty with distinguishing between hot
and cold water*
Problems with standing/walking because
of difﬁculty feeling ground under feet*
Pain and tingling in ﬁngers/hands
or toes/feet†
Prescription medication use‡
Autonomic neuropathy A little Quite a bit Very much NA
Dizzy when standing up from a sitting
or lying position*
Hearing loss/damage A little (difﬁculty hearing or
reduced hearing) or yes
(persistent dizziness or
vertigo)
Quite a bit or very much
(difﬁculty hearing or
reduced hearing)
Hearing loss that requires
a hearing aid in one or both
ears or complete deafness
in one ear
Complete deafness
in both ears
Difﬁculty hearing*
Reduced hearing†
Hearing loss that requires a hearing aid§
Complete deafness§
Persistent dizziness or vertigo§
Tinnitus A little Quite a bit Very much NA
Ringing in ears†
Raynaud phenomenon A little Quite a bit Very much NA
White, cold ﬁngers/hands or toes/feet
when it is cold†
Pain A little bit Moderately or quite a bit or
medication use
Extremely NA
How much pain interferes in normal
work (including work outside the
home, inside the house, in the yard)k
Prescription medication use‡
Kidney disease Have condition Have condition and
medication use
NA NA
Told by physician of condition
Prescription medication use‡
Hypercholesterolemia NA Have condition and
medication use
NA NA
Told by physician of condition
Prescription medication use for high total
cholesterol or low HDL cholesterol‡
Hypertriglyceridemia NA Medication use for condition NA NA
Prescription medication use‡
Hypertension NA Have condition and
medication use
NA NA
Told by physician of condition
Prescription medication use‡
Diabetes NA Have condition and taking
tablets or pills
Have condition and taking
insulin
NA
Told by physician of condition
Prescription medication use‡
(continued on following page)
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Table A1. AHOs That Comprise the Cumulative Burden of Morbidity Score (continued)
AHO and Platinum Study Items Used to Assign
Severity Grade
Grade
1 2 3 4
Coronary artery disease Have angina or coronary
artery disease
Have angina or coronary
artery disease and either
medication use,
angioplasty, or stent
placement
Had heart attack or
myocardial infarction or
have had coronary bypass
surgery
NA
Told by physician of condition, angina
Told by physician of condition, coronary
artery disease
Heart attack or myocardial infarction
Had relevant procedure
Transient ischemic attack Have condition NA NA NA
Told by physician of condition
Stroke NA Have condition NA Have condition and
had carotid artery
surgery
Told by physician of condition
Surgical procedure
Peripheral artery disease Have condition Have condition and
medication use
Have condition and had
peripheral artery surgery
NA
Pain in calf when walking (intermittent
claudication)
Had relevant procedure
Prescription medication use‡
Thromboembolic event NA Have deep vein thrombosis Have pulmonary embolism or
medication use
NA
Blood clot in leg (deep vein thrombosis)
Blood clot in lung (pulmonary embolism)
Prescription medication use‡
Obesity, BMI,¶ kg/m2 NA 25-29 30-39 $ 40
Thyroid disease Have condition Have condition and
medication use
NA NA
Overactive thyroid
Underactive thyroid
Prescription medication use‡
Anxiety/depression NA Medication use for condition NA NA
Prescription medication use‡
Erectile dysfunction A little Quite a bit or very much or
medication use
NA NA
Difﬁculty with getting or maintaining an
erection*
Prescription medication use‡
Hypogonadism NA Medication use for condition NA NA
Prescription medication use‡
NOTE. For conditions that are based on more than one question, the severity grade was assigned according to the response that reported the greatest or most severe
symptom.
Abbreviations: AHO, adverse health outcome; BMI, bodymass index; HDL, high-density lipoprotein; NA, not applicable (data needed to assign gradewere not captured).
*Assessed with the European Organisation for Research and Treatment of Cancer Chemotherapy-Induced Peripheral Neuropathy 20-item quality-of-life questionnaire
on the basis of symptoms experienced over the past 4 weeks.68 For each item, participants were asked whether the symptom started before, during, or after
chemotherapy. If participants responded that the symptoms started before chemotherapy, those responses were not considered when assigning severity grade.
†Assessed with the Scale for Chemotherapy-Induced Long-Term Neurotoxicity questionnaire on the basis of symptoms experienced over the past 4 weeks.69 For each
item, participants were asked whether the symptom started before, during, or after chemotherapy. If participants responded that the symptom started before
chemotherapy, those responses were not considered when assigning severity grade.
‡Prescriptionmedications taken for at least the past 4weekswere only used to assign grade if the participant reported that the indicationwas for the given AHO and that
the medication was started during or after chemotherapy.
§Item is from the Hearing Handicap Inventory by Ventry and Weinstein70 and assessed symptoms at the time of clinical evaluation. For each item, participants were
asked to report the age (in years) at ﬁrst occurrence. If onset of symptomswas before their age of germ cell tumor diagnosis, those responseswere not considered when
assigning severity grade.
kItem is from the 36-Item Short Form Survey and assessed symptoms experienced over the past 4 weeks.71
¶BMI is based on physical examination performed at time of clinical assessment.
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Table A2. Deﬁnition of the Cumulative Burden of Morbidity Score on the Basis of Number and Severity of Individual Adverse Health Outcomes
Grade None Very Low Low Medium High Very High Severe
1 0 $ 1 Any number Any number Any number Any number Any number
2 0 0 $ 1 Any number Any number Any number Any number
3 0 0 0 $ 1 $ 2 # 1 $ 2
4 0 0 0 0 0 1 1
NOTE.Methods adapted fromGeenen et al.15Modiﬁcations include division of the low category into very low and low and division of the high category into high and very
high to reﬂect the granularity of data collected in the current study.
Table A3. Association Among Clinical, Sociodemographic, and Health Behavior Factors and Cumulative Burden of Morbidity Score
Variable
Cumulative Burden of Morbidity Score, No. (%)
PNone Very Low Low Medium High
Very High/
Severea
No. of participants 65 104 458 360 180 47
Mean age at evaluation, years (SD) 32 (8.5) 36 (9.6) 38 (10.0) 39 (10.2) 42 (10.2) 39 (11.3) , .001
Mean age at diagnosis, years (SD) 27 (7.3) 30 (8.4) 31 (8.2) 31 (8.8) 34 (9.4) 33 (8.4) , .001
Mean years since treatment (SD)b 4.5 (4.2) 5.7 (5.1) 6.5 (5.6) 6.5 (6.1) 6.4 (6.2) 4.7 (4.8) .020
Racec .002
White 49 (4.7) 82 (7.9) 397 (38.3) 309 (29.8) 161 (15.5) 38 (3.7)
African American 0 3 (18.8) 3 (18.8) 4 (25.0) 3 (18.8) 3 (18.8)
Asian 7 (11.9) 11 (18.6) 22 (37.3) 14 (23.7) 5 (8.5) 0
Other 6 (8.8) 6 (8.8) 22 (32.4) 22 (32.4) 8 (11.8) 4 (5.9)
Educationd , .001
High school education or less 4 (2.9) 6 (4.3) 42 (30.2) 46 (33.1) 31 (22.3) 10 (7.2)
Post–high school training or some college 12 (4.2) 25 (8.7) 88 (30.5) 88 (30.5) 62 (21.5) 14 (4.8)
College or postcollege graduate 49 (6.3) 73 (9.3) 328 (41.9) 224 (28.6) 86 (11.0) 23 (2.9)
Marital statuse .016
Single/never married 26 (6.7) 38 (9.8) 148 (38.1) 107 (27.5) 48 (12.3) 22 (5.7)
Married/living as married 37 (5.0) 63 (8.5) 275 (37.2) 232 (31.4) 111 (15.0) 22 (3.0)
Divorced/separated 1 (1.4) 2 (2.8) 30 (42.3) 16 (22.5) 18 (25.7) 3 (4.3)
Current employment statusf , .001
Employed 57 (5.3) 87 (8.1) 426 (39.6) 328 (30.5) 143 (13.3) 36 (3.3)
Unemployed 5 (6.7) 11 (14.9) 22 (29.7) 18 (24.3) 12 (16.2) 6 (8.1)
Retired 0 3 (20.0) 3 (20.0) 3 (20.0) 6 (40.0) 0
Disability 0 1 (3.3) 3 (10.0) 7 (23.3) 16 (53.3) 3 (10.0)
Smoking statusg .036
Never 48 (6.9) 72 (10.1) 267 (37.4) 202 (28.3) 92 (12.9) 33 (4.6)
Former 14 (3.6) 26 (6.6) 151 (38.5) 122 (31.1) 68 (17.4) 11 (2.8)
Current 3 (2.8) 6 (5.6) 39 (36.5) 36 (33.6) 20 (18.7) 3 (2.8)
No. of alcoholic drinks in past yearh .001
Rarely/never 11 (4.6) 18 (7.5) 81 (33.9) 67 (28.0) 46 (19.3) 16 (6.7)
1-3/mo 13 (7.2) 12 (6.7) 63 (35.0) 52 (28.9) 27 (15.0) 13 (7.2)
1-6/wk 33 (5.8) 62 (10.9) 219 (38.5) 169 (29.7) 72 (12.7) 14 (2.5)
$ 1/d 7 (3.2) 11 (5.1) 92 (42.2) 70 (32.1) 35 (16.1) 3 (1.4)
Engage in vigorous physical activityi , .001
No 14 (3.7) 20 (5.3) 123 (32.5) 116 (30.7) 76 (20.1) 29 (7.7)
Yes 51 (6.1) 84 (10.1) 334 (40.0) 244 (29.2) 104 (12.5) 18 (2.2)
Retroperitoneal lymph node dissectionj .110
No 39 (6.1) 50 (7.8) 227 (35.4) 199 (31.0) 95 (14.9) 32 (5.0)
Yes 26 (4.6) 53 (9.4) 228 (40.4) 159 (28.2) 83 (14.7) 15 (2.7)
Bleomycin .580
No 25 (5.2) 42 (8.7) 195 (40.5) 134 (27.8) 71 (14.7) 15 (3.1)
Yes 40 (5.5) 62 (8.5) 263 (35.9) 226 (30.9) 109 (14.9) 32 (4.4)
(continued on following page)
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Table A3. Association Among Clinical, Sociodemographic, and Health Behavior Factors and Cumulative Burden of Morbidity Score (continued)
Variable
Cumulative Burden of Morbidity Score, No. (%)
PNone Very Low Low Medium High
Very High/
Severea
Type of chemotherapyk 3 No. cycles .190
EP 3 4 15 (4.3) 35 (9.9) 146 (41.4) 99 (28.1) 48 (13.6) 10 (2.8)
BEP 3 3 31 (6.7) 40 (8.7) 169 (36.7) 138 (30.0) 59 (12.8) 23 (5.0)
BEP 3 4 9 (4.1) 16 (7.2) 88 (36.0) 66 (29.7) 43 (19.4) 8 (3.6)
VIP 3 4 2 (6.5) 0 9 (29.0) 13 (40.6) 7 (21.9) 1 (3.1)
Abbreviations: BEP, bleomycin, etoposide, and cisplatin; EP, etoposide plus cisplatin; SD, standard deviation; VIP, etoposide, ifosfamide, and cisplatin.
aCategories were collapsed because of sparse data. Among the 47 participants, 46 had a cumulative burden of morbidity score of very high and one had a score of
severe.
bP value derives from analysis of log-transformed values as a result of unequal variance between groups. Means and SDs are from untransformed values.
cData on race were not available for 35 participants.
dData on education level were not available for three participants.
eData on marital status were not available for 15 participants.
fData on employment status were not available for 19 participants.
gData on smoking status were not available for 19 participants.
hData on alcohol consumption were not available for nine participants.
iData on physical activity were not available for one participant.
jData on retroperitoneal lymph node dissection were not available for 13 participants.
kOther chemotherapy regimens not included in the comparisons are EP other than four cycles (n = 28), BEP other than three or four cycles (n = 28), VIP other than four
cycles (n = 12), and other platinum-based regimens (n = 72).
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